Laidlaw initiated coverage of Senti Bio (SNTI) with a Buy rating and $5 price target Senti is an early clinical stage oncology-emphasized biotech company that focuses on a novel and differentiated CAR-NK therapy, SENTI-202, as a potential high-risk relapsed or refractory acute myeloid leukemia treatment, the analyst tells investors in a research note. The firm says the company recently reported “very promising” Phase I interim results.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNTI:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue